ARGX-113 is a novel FcRN antagonist shown to lower immunoglobulin levels in animals and man. This mechanism of action is now being studied in autoimmune diseases such as myasthenia gravis
ARGX-113 is a novel FcRN antagonist shown to lower immunoglobulin levels in animals and man. This mechanism of action is now being studied in autoimmune diseases such as myasthenia gravis
To assess the safety and preliminary efficacy of ARGX-113 in generalized myasthenia gravis.
As above
Generalized myasthenia gravis, MGFA Class II to IVa, MG-ADL score at least 5, on stable immunosuppressive therapy or other agents for at least 3 months. Patients will receive the novel agent as an infusion of 10mg/kg versus placebo each week for 4 weeks, then are followed for an additional two months to assess persistence of response.
None
Gil I. Wolfe, Nicholas J. Silvestri
Name: Connie Brand
Phone: 716-859-7620
Email: conniebr@buffalo.edu